Pfäffikon (SZ) Switzerland 5th of June 2023: Saiba Animal Health AG announced today the achievement of an important project milestone stemming from a partnership agreement initiated in December 2020 with Boehringer Ingelheim, a global leader in animal health. Based on promising preclinical results in the target species, Boehringer Ingelheim exercised an option to take an exclusive license for the commercialization and development of Saiba’s product candidate.

Dr. Gary T. Jennings, CEO of Saiba Animal Health AG commented: “The execution of the development and commercialization option by Boehringer Ingelheim is a significant milestone for Saiba and is driven by a convincing preclinical data-set generated by Boehringer Ingelheim’s and Saiba Animal Health’s R&D teams. We very much look forward to the product candidate advancing into development and achieving its potential to address a significant unmet veterinary need. Boehringer Ingelheim’s continued investment in the product candidate acknowledges the potential for our platform technology and pipeline projects to be translated into cost effective therapies for companion animals.”

The license execution triggers an upfront payment which Saiba Animal Health AG will invest to further advance its technology and other pipeline candidates.

For additional Information, please contact:
Saiba Animal Health AG
Pfäffikon (SZ)
Switzerland
Gary T. Jennings, PhD
CEO
gary.jennings@saiba-animalhealth.com
gary.jennings@usz.ch